Codexis, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Codexis, Inc. on February 17, 2012. The report discloses significant changes in corporate leadership, specifically the resignation of the President and Chief Executive Officer and the appointment of an interim successor.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation arrangements and personnel changes.
Material Changes
- Executive Departure: Dr. Alan Shaw resigned effective immediately as Director, President, and Chief Executive Officer to pursue other interests. The resignation was not due to any disagreement with the Company regarding operations, policies, or practices.
- Interim Appointment: Peter Strumph, previously Senior Vice President and Business Head of Pharmaceuticals, was appointed as interim President and Chief Executive Officer.
- Search Committee: The Board of Directors has formed a search committee to oversee the transition and identify a permanent CEO from internal and external candidates.
Compensation, Risks, and Contingencies
Dr. Shaw entered into a Transition and Separation Agreement with the following material terms:
- Consulting Period: Dr. Shaw will provide consulting services until August 17, 2012, receiving his current base salary of $42,083.34 per month. Stock options will continue to vest per existing terms.
- Post-Consulting Benefits: Upon completion of the consulting period and execution of a release of claims, Dr. Shaw is entitled to:
- Twelve (12) months of base salary.
- A fiscal year 2011 bonus of $220,500.00 (less withholding taxes).
- COBRA premium reimbursement until August 17, 2013, or until comparable coverage is obtained.
- Reimbursement for legal and tax advisor fees up to $7,500.
- Stock Options: Options may remain exercisable until March 31, 2013, the original expiration date, or a Change in Control, whichever is earlier.
- Non-Compete: Dr. Shaw agreed not to become employed by or assist any competitor during the consulting period.
Mr. Strumph has entered into standard indemnification and change of control severance agreements consistent with those filed in the Company's 2010 Form S-1.
Investor Verification Checklist
- Verify the full text of the Transition and Separation Agreement to be filed as an exhibit to the Annual Report on Form 10-K for the fiscal year ended December 31, 2011.
- Monitor the progress of the search committee for a permanent CEO.
- Review the press release (Exhibit 99.1) for additional context on the leadership transition.
- Confirm the impact of the leadership change on the Company's strategic direction in upcoming quarterly reports.